Interdisciplinary Management of Perianal Crohn's Disease

Research output: Contribution to journalReview article

Abstract

Perianal disease is a common manifestation of Crohn disease (CD) that results in significant morbidity and decreased quality of life. Despite several medical and surgical options, complex perianal CD remains difficult to treat. Before the advent of biologic therapy, antibiotics were the mainstay of medical treatment. Infliximab remains the most well-studied medical therapy for perianal disease. Surgical interventions are limited by the risk of nonhealing wounds and potential incontinence. When treatment options fail, fecal diversion or proctectomy may be necessary. Stem cell therapies may offer improved results and seem to be safe, but are not yet widely used.

Original languageEnglish (US)
Pages (from-to)547-562
Number of pages16
JournalGastroenterology Clinics of North America
Volume46
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Crohn Disease
Biological Therapy
Cell- and Tissue-Based Therapy
Stem Cells
Therapeutics
Quality of Life
Anti-Bacterial Agents
Morbidity
Wounds and Injuries
Infliximab

Keywords

  • Combined medical and surgical management
  • Crohn's disease
  • Perianal fistulizing disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Interdisciplinary Management of Perianal Crohn's Disease. / Lightner, Amy; Faubion, William Alvis; Fletcher, Joel Garland.

In: Gastroenterology Clinics of North America, Vol. 46, No. 3, 01.09.2017, p. 547-562.

Research output: Contribution to journalReview article

@article{9e7ed7b37bad4b1983488e10e30727c0,
title = "Interdisciplinary Management of Perianal Crohn's Disease",
abstract = "Perianal disease is a common manifestation of Crohn disease (CD) that results in significant morbidity and decreased quality of life. Despite several medical and surgical options, complex perianal CD remains difficult to treat. Before the advent of biologic therapy, antibiotics were the mainstay of medical treatment. Infliximab remains the most well-studied medical therapy for perianal disease. Surgical interventions are limited by the risk of nonhealing wounds and potential incontinence. When treatment options fail, fecal diversion or proctectomy may be necessary. Stem cell therapies may offer improved results and seem to be safe, but are not yet widely used.",
keywords = "Combined medical and surgical management, Crohn's disease, Perianal fistulizing disease",
author = "Amy Lightner and Faubion, {William Alvis} and Fletcher, {Joel Garland}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.gtc.2017.05.008",
language = "English (US)",
volume = "46",
pages = "547--562",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Interdisciplinary Management of Perianal Crohn's Disease

AU - Lightner, Amy

AU - Faubion, William Alvis

AU - Fletcher, Joel Garland

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Perianal disease is a common manifestation of Crohn disease (CD) that results in significant morbidity and decreased quality of life. Despite several medical and surgical options, complex perianal CD remains difficult to treat. Before the advent of biologic therapy, antibiotics were the mainstay of medical treatment. Infliximab remains the most well-studied medical therapy for perianal disease. Surgical interventions are limited by the risk of nonhealing wounds and potential incontinence. When treatment options fail, fecal diversion or proctectomy may be necessary. Stem cell therapies may offer improved results and seem to be safe, but are not yet widely used.

AB - Perianal disease is a common manifestation of Crohn disease (CD) that results in significant morbidity and decreased quality of life. Despite several medical and surgical options, complex perianal CD remains difficult to treat. Before the advent of biologic therapy, antibiotics were the mainstay of medical treatment. Infliximab remains the most well-studied medical therapy for perianal disease. Surgical interventions are limited by the risk of nonhealing wounds and potential incontinence. When treatment options fail, fecal diversion or proctectomy may be necessary. Stem cell therapies may offer improved results and seem to be safe, but are not yet widely used.

KW - Combined medical and surgical management

KW - Crohn's disease

KW - Perianal fistulizing disease

UR - http://www.scopus.com/inward/record.url?scp=85028663356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028663356&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2017.05.008

DO - 10.1016/j.gtc.2017.05.008

M3 - Review article

C2 - 28838414

AN - SCOPUS:85028663356

VL - 46

SP - 547

EP - 562

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 3

ER -